...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.
【24h】

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

机译:浅表性膀胱癌的GP-170表达,预后和化学耐药性之间的相关性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. MATERIALS AND METHODS: GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations in grade and stage at recurrence and modifications in GP-170 expression were also studied. RESULTS: No significant correlation between GP-170 expression and G-grade and T-category was found. A significant correlation was detected between GP-170 expression and recurrence ( P=0.0383). It showed a biphasic pattern, i.e., tumors that did not express GP-170 had a higher recurrence rate, but high GP-170 levels were also associated with an increasing risk of recurrence. Intravesical chemotherapy did not induce significative variations in GP-170 expression. No correlation was found between progression and GP-170. CONCLUSION: GP-170 seems to be an independent prognostic factor for recurrence in superficial bladder tumors. A negative GP-170 pattern and high levels of GP-170 are associated with an increasing risk of recurrence but have no impact upon progression. In our experience, GP-170 is neither induced nor modified by intravesical chemotherapy, although it might represent a factor of chemoresistance when strongly expressed.
机译:目的:在初诊和复发时研究GP-170在浅表性膀胱癌中的作用,并评估膀胱内化学预防是否能改变GP-170在肿瘤复发中的表达。材料与方法:对160例原发性膀胱浅表移行细胞癌患者进行了回顾性评估,随访时间长达10年。经尿道切除术(TUR)复发84例(52.5%)。 TUR术后行膀胱辅助化疗52例。研究了GP-170与G级,T类,复发和进展风险以及辅助膀胱内化疗的采用之间的相关性。还研究了复发时分级和阶段变化与GP-170表达修饰之间的相关性。结果:GP-170的表达与G等级和T类别之间无显着相关性。在GP-170表达与复发之间检测到显着相关性(P = 0.0383)。它显示出双相模式,即,不表达GP-170的肿瘤具有较高的复发率,但是高GP-170水平也与复发风险增加相关。膀胱内化疗未诱导GP-170表达的显着变化。进展与GP-170之间未发现相关性。结论:GP-170似乎是浅表性膀胱肿瘤复发的独立预后因素。阴性的GP-170模式和高水平的GP-170与复发风险增加相关,但对进展没有影响。根据我们的经验,GP-170既不被膀胱内化疗诱导也不被修饰,尽管在强烈表达时它可能代表化学抗性的一个因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号